Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics

Cystic fibrosis is realizing the promise of personalized medicine. Recent advances in drug development that target the causal CFTR directly result in lung function improvement, but variability in response is demanding better prediction of outcomes to improve management decisions. The genetic modifie...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Hum Mol Genet
Main Authors: Strug, Lisa J., Gonska, Tanja, He, Gengming, Keenan, Katherine, Ip, Wan, Boëlle, Pierre-Yves, Lin, Fan, Panjwani, Naim, Gong, Jiafen, Li, Weili, Soave, David, Xiao, Bowei, Tullis, Elizabeth, Rabin, Harvey, Parkins, Michael D., Price, April, Zuberbuhler, Peter C., Corvol, Harriet, Ratjen, Felix, Sun, Lei, Bear, Christine E., Rommens, Johanna M.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2016
Assuntos:
Association Studies Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5886039/
https://ncbi.nlm.nih.gov/pubmed/28171547
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/hmg/ddw290
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados